Vincenzo De Giorgi, Gabriella Perillo, Giovanni Cecchi, Federica Fazzari, Biancamaria Zuccaro
classification.This contrasts with prior studies suggesting that aggressive subtypes such as morpheaform or infiltrative BCCs are associated with reduced response rates.Limitations include the retrospective design, small sample, heterogeneous tumor sites and subtypes, absence of molecular profiling, and lack of comparison with other HPIs.Accordingly, these data cannot establish tumor size as an independent predictor.Nevertheless, the finding that larger LA-BCCs may show an earlier visible response is novel, clinically relevant, and suitable for prospective validation in larger cohorts.